We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

14 hedge funds and large institutions have $607K invested in Altamira Therapeutics Ltd in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

303% more call options, than puts

Call options by funds: $117K | Put options by funds: $29K

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

13% less funds holding

Funds holding: 16 → 14 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

41% less capital invested

Capital invested by funds: $1.03M → $607K (-$421K)

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
5
Calls
$117K
Puts
$29K
Net Calls
+$88K
Net Calls Change
-$51K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$33.8K
2
HF
HRT Financial
New York
+$21.2K
3
IC
Ikarian Capital
Texas
+$18.4K
4
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$1.45K
5
GI
Gradient Investments
Minnesota
+$1.45K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$31.9K
2
Simplex Trading
Simplex Trading
Illinois
-$21.7K
3
TSS
Two Sigma Securities
New York
-$19K
4
Jane Street
Jane Street
New York
-$18K
5
TRCT
Tower Research Capital (TRC)
New York
-$8.21K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$351K +$18.4K +38 +5%
BlackRock
2
BlackRock
New York
$67K +$33.8K +70 +83%
Group One Trading
3
Group One Trading
Illinois
$58K +$1.45K +3 +2%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$40K -$31.9K -66 -42%
BFM
5
Boothbay Fund Management
New York
$34K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$20K – – –
HF
7
HRT Financial
New York
$19K +$21.2K +44 New
Morgan Stanley
8
Morgan Stanley
New York
$9K +$483 +1 +5%
UBS Group
9
UBS Group
Switzerland
$4K -$4.35K -9 -50%
CG
10
Cutler Group
California
$2K +$966 +2 +67%
Wells Fargo
11
Wells Fargo
California
$1K – – –
1832 Asset Management
12
1832 Asset Management
Ontario, Canada
$1K +$1.45K +3 New
GI
13
Gradient Investments
Minnesota
$1K +$1.45K +3 New
Simplex Trading
14
Simplex Trading
Illinois
– -$21.7K -45 -96%
TSS
15
Two Sigma Securities
New York
– -$19K -26 Closed
Jane Street
16
Jane Street
New York
– -$18K -25 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$8.21K -17 Closed
Osaic Holdings
18
Osaic Holdings
Arizona
– -$483 -1 Closed

CYTO Hedge Fund Activity: Q1 2022 in Review

14 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2022, worth a combined $607K — down 41% from $1.03M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CYTO and 3 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was BlackRock, adding an estimated $33.8K. The largest seller was Susquehanna International Group, cutting an estimated $31.9K.

  • 14 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2022, down from 16 in Q4 2021.
  • Funds reported $607K of Altamira Therapeutics Ltd stock for Q1 2022, down 41% quarter-over-quarter.
  • 3 funds opened new Altamira Therapeutics Ltd positions in Q1 2022 and 5 closed out, a net change of -2 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q1 2022 was BlackRock, an estimated $33.8K added.
  • The largest Altamira Therapeutics Ltd seller in Q1 2022 was Susquehanna International Group, an estimated $31.9K sold.

Based on aggregated 13F filings for Q1 2022.